Knott David M Jr Acquires 45,001 Shares of TG Therapeutics, Inc. $TGTX

Knott David M Jr lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 100.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 90,001 shares of the biopharmaceutical company’s stock after buying an additional 45,001 shares during the quarter. TG Therapeutics makes up about 1.8% of Knott David M Jr’s holdings, making the stock its 17th largest holding. Knott David M Jr’s holdings in TG Therapeutics were worth $2,990,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Danske Bank A S bought a new position in TG Therapeutics in the third quarter valued at approximately $25,000. Hantz Financial Services Inc. increased its position in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 573 shares in the last quarter. Truvestments Capital LLC increased its position in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $52,000. 58.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on TGTX. Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Bank of America lifted their price target on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. HC Wainwright boosted their price target on TG Therapeutics from $70.00 to $77.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.33.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $55.50 on Friday. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $59.30. The company’s fifty day simple moving average is $48.69 and its 200-day simple moving average is $37.89. The firm has a market cap of $8.50 billion, a PE ratio of 19.41, a P/E/G ratio of 1.32 and a beta of 1.60. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. During the same period last year, the business posted $0.03 EPS. The firm’s revenue for the quarter was up 69.5% on a year-over-year basis. Equities research analysts expect that TG Therapeutics, Inc. will post 1.46 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.